Published in

American Chemical Society, Journal of Proteome Research, 10(12), p. 4627-4641, 2013

DOI: 10.1021/pr4005794

Links

Tools

Export citation

Search in Google Scholar

Quantitative Proteomic Analysis of Microdissected Breast Cancer Tissues: Comparison of Label-Free and SILAC-based Quantification with Shotgun, Directed, and Targeted MS Approaches

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
  • Must obtain written permission from Editor
  • Must not violate ACS ethical Guidelines
Orange circle
Postprint: archiving restricted
  • Must obtain written permission from Editor
  • Must not violate ACS ethical Guidelines
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Quantitative proteomics plays an important role in validation of breast cancer related biomarkers. In this study, we systematically compared performance of label-free quantification (LFQ) and SILAC with shotgun and directed methods for quantifying breast cancer related markers in microdissected tissues. We show that LFQ leads to slightly higher coefficient of variation (CV) for protein quantification (median CV=16.3%) than SILAC quantification (median CV=13.7%) (P<0.0001), but LFQ method enables ~60% more protein quantification and is also more reproducible (~20% more proteins were quantified in all replicate samples). Furthermore, we describe a method to accurately quantify multiple proteins within one pathway, i.e. "focal adhesion pathway", in trace amounts of breast cancer tissues using a SILAC-based SRM assay. Using this SILAC-based SRM assay, we precisely quantified five "focal adhesion" proteins with good quantitative precision (CV range: 2.4%-5.9%) in replicate whole tissue lysate samples, and replicate microdissected samples (CV range: 5.8%-16.1%). Our results show that in microdissected breast cancer tissues, LFQ in combination with shotgun proteomics performed overall best and is therefore suitable for both biomarker discovery and validation in these types of specimens. The SILAC-based SRM method can be used for development of clinically relevant protein assays in tumor biopsies.